Singularly focused on improving the lives of patients with severe autoimmune diseases such as systemic lupus erythematosus (SLE) and Sjögren’s syndrome. The company has leveraged recent scientific advances to develop new, highly targeted, safer therapies for these diseases, and is at the forefront of pioneering a completely new approach to treating Lupus and Sjögren’s syndrome.
Phase l or ll, Pre-Clinical Stage
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.